China to make all hospitals offer epidurals to incentivise childbirth
Hong Kong: China said that by the end of this year all tertiary level hospitals must offer epidural anaesthesia during childbirth, a move it said would help promote a "friendly childbearing environment" for women.
Tertiary hospitals - those with more than 500 beds, must provide epidural anaesthesia services by 2025 while secondary hospitals - those containing more than 100 beds - must provide the services by 2027, China's National Health Commission (NHC) said in a statement last week.
Authorities are struggling to boost birth rates in the world's second largest economy after China's population fell for a third consecutive year in 2024 with experts warning the downturn will worsen in the coming years.
Around 30% of pregnant women in China receive anaesthesia to relieve pain during childbirth, compared with more than 70% in some developed countries, the official China Daily said.
The World Health Organization recommends epidurals for healthy pregnant women requesting pain relief and it is widely utilised in many countries around the world, including France, where around 82% of pregnant women opt to have one, and in the United States and Canada where more than 67% do.
The move will "improve the comfort level and security of medical services" and "further enhance people's sense of happiness and promote a friendly childbearing environment," the NHC said.
A growing number of provinces across China are also beginning to include childbirth anaesthesia costs as part of their medical insurance schemes to encourage more women to have children.
High childcare costs as well as job uncertainty and a slowing economy have discouraged many young Chinese from getting married and starting a family.
In June, health authorities in China's southwestern Sichuan province proposed to extend marriage leave up to 25 days and maternity leave up to 150 days, to help create a "fertility-friendly society."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
11 hours ago
- Hindustan Times
Engineering humanity & where to draw a line
The future of human reproduction and genetic design is accelerating faster than most people understand, driven not by national debates or international accords, but by software startups, biotech investors, and quiet breakthroughs in fertility clinics. Nucleus Genomics recently unveiled Nucleus Embryo, a genetic screening platform that allows prospective parents to assess up to 20 embryos for more than 900 conditions and traits. These include not only polygenic risk scores for diseases such as cancer and Alzheimer's but also traits such as intelligence, height, and anxiety. In short, it offers a pathway to genetic optimisation — allowing parents to select not only healthier babies but the human features they want. Orchid, another US startup, pioneered full-genome sequencing of IVF embryos for disease screening. Once exclusive to the ultra-wealthy, Orchid's services are rapidly becoming more affordable, pointing to a future where embryo selection could become a standard step in family planning for both the middle and upper class. Meanwhile, Coinbase CEO Brian Armstrong, known for backing radical biotech ventures, has announced plans to launch a US company that would go beyond selection into embryo editing. Thanks to recent advances in base editing, it is now possible to alter individual DNA letters with high precision rewriting, rather than merely reading the code of life. The commercial race toward Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) babies has begun — and this is something I have long been both excited and terrified about. In a 2017 Washington Post article, I asked: 'Human editing has just become possible. Are we ready for the consequences?' I warned that CRISPR had made embryo editing technically feasible, but that society wasn't prepared for the moral fallout. I feared we would drift from preventing disease to designing our children. We have crossed this Rubicon. While the global community debates ethics and oversight, China is racing ahead with few restraints. Chinese scientists are editing the genes of animals — and even human embryos — not only to treat disease but to enhance traits such as intelligence and strength. Their goal appears to be the creation of so-called superhumans. Without international standards and ethical guardrails, unchecked ambition in any one country can pose risks for all of humanity. India must pay close attention. It has already misused reproductive technology: Ultrasound machines meant for foetal health monitoring were widely repurposed for sex selection. In Haryana, the sex ratio at birth has declined to 910 girls for every 1,000 boys. In a society shaped by caste, colourism, and academic pressure, gene editing could easily be co-opted to entrench inequality under the banner of 'better futures'. But more than vigilance, India must lead. With a deep-rooted traditions of spiritualism, karma and ethics, and respect for human dignity, it is uniquely positioned to offer the moral leadership this moment demands. Its scientific community is world-class, and its track record — from generic medicine to vaccine equity — shows it can pair innovation with compassion. The concerns extend far beyond reproduction. Gene-edited crops could marginalise small farmers if patented seeds are controlled by large corporations. CRISPR-based therapies, already costing more than $500,000 in the West, could deepen biological inequality. Even gene drives, designed to eliminate diseases such as malaria, could threaten delicate ecosystems like the Sundarbans if not deployed with care. To lead responsibly, India must act on four fronts. First, accelerate research. Universities and public institutions should partner with socially responsible entrepreneurs to build local expertise in gene editing, synthetic biology, and bioethics. This collaboration can ensure innovation is aligned with the public interest and rooted in Indian values rather than imported priorities. Second, access must be equitable. India has done this before with lifesaving generic drugs and can do this again. Public funding and subsidies must ensure CRISPR therapies reach rural and tribal populations suffering from genetic disorders like thalassemia. Third, the entire regulatory framework needs to be updated because existing biotech laws predate CRISPR. A new structure, co-created with scientists, ethicists, civil society, and patients, must define what is allowed, what is off-limits, and how oversight will function. Real engagement with the public, not just top-down mandates, will be essential. Fourth, India must lead globally. As it did in championing affordable vaccines, it can help shape international norms for genetic science, banning non-medical trait selection, regulating gene drives, and insisting on transparency and accountability. India can set the ethical benchmark, not merely follow it. We now have a rare opportunity to prove that scientific progress and moral clarity can coexist, but the window is narrow. We cannot rely on Silicon Valley, where profit is the only true metric of success, nor on China, where State control and repression define scientific ambition. Both paths risk taking humanity into dangerous territory. The world needs a third way, rooted in spiritual values, ethical reasoning, and the belief that technology must serve the many, not just the powerful, and this is the role India must play. Vivek Wadhwa is CEO, Vionix Biosciences. The views expressed are personal.
Mint
17 hours ago
- Mint
Chinese Firm Halts Production of Controversial Alzheimer's Drug
(Bloomberg) -- A Chinese company that developed the country's first indigenous therapy for Alzheimer's disease has suspended production and sales of the drug, casting doubts on the treatment's future. The drug's license has expired and its renewal is now in the final stages of a regulatory review, during which it must stop commercial production and sales, Green Valley Pharmaceutical Co. said in an emailed statement to Bloomberg News on Tuesday. The Shanghai-based drugmaker informed employees of the production halt in an internal notice at the end of May, local media Yicai reported first on Monday. Green Valley's drug — a seaweed-derived compound known as sodium oligomannate, or GV-971 — was hailed as a major advance when China's drug regulator gave it conditional approval in 2019, as the first new therapy endorsed for Alzheimer's in 17 years. Local and international medical experts have since questioned how effective it really is in slowing or reversing the cognitive declines of Alzheimer's patients given the relatively short duration of — and the inconsistent results shown in — its late-stage clinical trial in China. The company launched a global clinical trial in 2020, seeking to enroll some 2,000 patients across China, the US and Europe. It was terminated two years later due to a lack of funding and Covid pandemic disruptions. Green Valley previously conducted post-marketing clinical studies on around 3,300 patients on sodium oligomannate in China and has planned to present the results at an international academic conference later this year, according to the company. The changes are temporary and limited to operations related to sodium oligomannate, the company said, adding that drug supply for clinical trials is unaffected. 'We are in close communications with relevant authorities and believe patients' treatment needs will be met soon,' it said in the email. The closely-held company has not disclosed sales revenue for GV-971 in China, where it was included for national insurance reimbursement in 2022 at a price of around $41 per box. Hospital and retail sales of GV-971 topped $45.4 million (326 million yuan) that year, Yicai reported, citing figures from Pharnexcloud — a database of national hospital sales in China. China has since approved two new Alzheimer's therapies developed by multinational drugmakers: Biogen Inc. and Eisai Co.'s Leqembi, and Kisunla from Eli Lilly & Co. The country has 17 million dementia patients — about 30% of the global total — per a 2024 report led by Shanghai Jiao Tong University School of Medicine. More stories like this are available on
&w=3840&q=100)
Business Standard
18 hours ago
- Business Standard
China to expand pain relief options for childbirth amid population decline
China has announced that all tertiary-level hospitals must offer epidural anaesthesia during labour by the end of this year. The directive, issued by the National Health Commission (NHC), is being seen as a step toward creating a more friendly childbearing environment, reported CNN. The mandate targets tertiary hospitals — those with more than 500 beds — and gives them a deadline of end-2025 to implement epidural services. Secondary hospitals with over 100 beds have until 2027 to follow suit. The decision comes at a critical time. China's population has declined for a third year in a row as of 2024, and demographers warn the trend could accelerate in the years ahead. Despite various incentives, young Chinese couples remain reluctant to marry and start families, citing high childcare costs, job instability, and a sluggish economy. Pain relief — or the lack of it — during childbirth is another piece of that puzzle. Currently, only about thirty per cent of pregnant women in China receive any form of anaesthesia during delivery, as reported by China Daily. That's significantly lower compared to countries like France, where eighty-two per cent of women choose an epidural, or the United States (US) and Canada, where the number stands at over sixty-seven per cent. Globally, epidurals are widely regarded as a safe and effective method of pain relief. The World Health Organization recommends their use for healthy pregnant women requesting relief during labour. But in many parts of China, epidurals remain either unavailable or unaffordable — with a shortage of trained anaesthesiologists adding to the problem. To bridge the gap, several provinces have now started including childbirth anaesthesia costs under public medical insurance, making it easier for women to opt in. The NHC believes these changes will bring about more than just comfort in delivery rooms.
